In a groundbreaking study led by Monash University and Harvard researchers, combining treatments for obstructive sleep apnoea (OSA) has shown significant benefits over single-treatment approaches. The findings, published in the European Respiratory Journal, highlight a new frontier in managing this common sleep disorder.
Obstructive sleep apnoea, a condition affecting about five percent of Australians, is particularly prevalent among men over 30, with a rate of one in four. The disorder is characterized by repeated interruptions in breathing during sleep, often due to narrowed airways and unstable breathing patterns. Until now, treatment strategies have largely focused on either anatomical or non-anatomical causes, but not both simultaneously.
Innovative Approach to OSA Treatment
The Monash-led trial, in collaboration with Brigham and Women’s Hospital in Boston, tested the efficacy of combining a ventilatory control intervention, specifically supplemental oxygen, with a mechanical intervention known as a mandibular advancement device (MAD). Associate Professor Brad Edwards from the Monash University School of Psychological Sciences explained the rationale behind this dual approach.
“OSA is due to a combination of anatomical and non-anatomical causes,” said Associate Professor Edwards. “The MAD targets the anatomical cause while oxygen helps target a leading but underappreciated non-anatomical cause.”
This multicentre randomised crossover trial involved 41 patients with moderate-to-severe OSA. Participants underwent a comprehensive overnight sleep study with four different interventions: oxygen, MAD, combination therapy, and a sham treatment using room air.
Results and Implications
The study’s results were compelling. The combination of supplemental oxygen and MAD significantly reduced the severity of OSA compared to each treatment alone. Senior author Scott Sands, an Associate Professor of Medicine at Brigham and Women’s Hospital, emphasized the importance of these findings.
“Targeting multiple causes of OSA significantly decreased severity, measured using a number of different metrics, compared to each therapy alone,” said Assistant Professor Sands. “If widely adopted, it could be a bit like people with high blood pressure taking 2-3 medications to control it, with each targeting different biological pathways.”
The study represents a pivotal shift in how OSA might be treated in the future, suggesting that a multi-faceted approach could offer better outcomes for patients.
Understanding Obstructive Sleep Apnoea
Obstructive sleep apnoea is primarily caused by the collapse or narrowing of the upper airway, particularly the pharynx, during sleep. This anatomical issue is often exacerbated by unstable breathing regulation, which can lead to repeated episodes of apnea and hypopnea throughout the night.
Historically, treatments have focused on either the anatomical aspect, using devices like MADs, or on improving breathing stability. However, the integration of these approaches, as demonstrated in this study, could mark a new era in OSA management.
Next Steps and Future Research
While the results are promising, the researchers acknowledge the need for larger trials to confirm the findings and refine treatment protocols. The study’s authors are calling for further research to identify which patients would benefit most from this combined treatment approach.
As the medical community continues to explore these findings, the potential for improved patient outcomes could lead to a paradigm shift in how obstructive sleep apnoea is treated globally.
For more detailed insights, the full research paper can be accessed at this link.
For media inquiries, please contact Cheryl Critchley, Media and Communications Manager (medical) at [email protected] or by phone at +61 (0) 477 571 442.
